Literature DB >> 28444199

Geographical differences in prescription of secondary preventive drug therapy after acute myocardial infarction in Norway.

Jarle Jortveit1, Sigrun Halvorsen2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28444199     DOI: 10.1093/ehjcvp/pvx008

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Pharmacother


× No keyword cloud information.
  5 in total

1.  Unsatisfactory risk factor control and high rate of new cardiovascular events in patients with myocardial infarction and prior coronary artery disease.

Authors:  Jarle Jortveit; Sigrun Halvorsen; Anete Kaldal; Are Hugo Pripp; Ragna Elise S Govatsmark; Jørund Langørgen
Journal:  BMC Cardiovasc Disord       Date:  2019-03-28       Impact factor: 2.298

2.  Long-term hospital-based secondary prevention of coronary artery disease: a randomized controlled trial.

Authors:  Anete Kaldal; Serena Tonstad; Jarle Jortveit
Journal:  BMC Cardiovasc Disord       Date:  2021-12-16       Impact factor: 2.298

3.  Geographical inequalities in the decreasing 28-day mortality following incident acute myocardial infarction: a Danish register-based cohort study, 1987-2016.

Authors:  Niels Asp Fuglsang; Elisabeth Zinck; Annette Kjær Ersbøll; Bjarne Kjær Ersbøll; Gunnar Hilmar Gislason; Thora Majlund Kjærulff; Kristine Bihrmann
Journal:  BMC Cardiovasc Disord       Date:  2022-03-04       Impact factor: 2.298

4.  Time trends in incidence, treatment, and outcome in acute myocardial infarction in Norway 2013-19.

Authors:  Jarle Jortveit; Are Hugo Pripp; Jørund Langørgen; Sigrun Halvorsen
Journal:  Eur Heart J Open       Date:  2022-08-10

5.  Outcomes after delayed primary percutaneous coronary intervention vs. pharmaco-invasive strategy in ST-segment elevation myocardial infarction in Norway.

Authors:  Jarle Jortveit; Are Hugo Pripp; Sigrun Halvorsen
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2022-08-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.